
Privacy notice | Accessibility statement | Terms and conditions | Login | Contact |
UK data driving real-world evidence
Bibliography
Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,700 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 4 March 2021) and papers are listed below and in the PDF below.
If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.
Download:
(PDF, 3MB, 220 pages)This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website.
Export 15 results:
Author [ Title
Filters: Author is Perez-Gutthann, S. [Clear All Filters]
“Cancer Incidence after Initiation of Antimuscarinic Medications for Overactive Bladder in the United Kingdom: Evidence for Protopathic Bias”, Pharmacotherapy, vol. 37, pp. 673-683, 2017.
, “A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs”, Br J Clin Pharmacol, vol. 48, pp. 847-52, 1999.
, , “GOLD assessment of COPD severity in the Clinical Practice Research Datalink (CPRD)”, Pharmacoepidemiol Drug Saf, 2018.
, “Hormone replacement therapy and incidence of acute myocardial infarction. A population-based nested case-control study”, Circulation, vol. 101, pp. 2572-8, 2000.
, “Low-dose diclofenac, naproxen, and ibuprofen cohort study”, Pharmacotherapy, vol. 19, pp. 854-9, 1999.
, “Methodological challenges when evaluating potential off-label prescribing of drugs using electronic health care databases: A case study of dabigatran etexilate in Europe”, Pharmacoepidemiol Drug Saf, vol. 27, pp. 713-723, 2018.
, “Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom”, PLoS One, vol. 13, p. e0204456, 2018.
, “A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder”, Curr Med Res Opin, p. 1, 2021.
, “Use of aclidinium did not increase the risk of death in a noninterventional cohort study in the Clinical Practice Research Datalink (CPRD), United Kingdom”, Respir Med, vol. 152, pp. 37-43, 2019.
, “Use of Topical Tacrolimus and Topical Pimecrolimus in Four European Countries: A Multicentre Database Cohort Study”, Drugs Real World Outcomes, 2018.
, “Validation of Cancer Cases Using Primary Care, Cancer Registry, and Hospitalization Data in the United Kingdom”, Epidemiology, vol. 29, pp. 308-313, 2018.
, “Validation of cardiovascular outcomes and risk factors in the Clinical Practice Research Datalink in the United Kingdom”, Pharmacoepidemiol Drug Saf, 2020.
, “Value of Free-text Comments for Validating Cancer Cases Using Primary-care Data in the United Kingdom”, Epidemiology, vol. 29, pp. e41-e42, 2018.
, “Variation in Cardiovascular Risk Related to Individual Antimuscarinic Drugs Used to Treat Overactive Bladder: A UK Cohort Study”, Pharmacotherapy, vol. 38, pp. 628-637, 2018.
,